Spyre Therapeutics, Inc. - Common Stock, $0.0001 par value (SYRE)

Historical Holders from Q3 2023 to Q3 2025

Symbol
SYRE on Nasdaq
CUSIP
00773J202
Type / Class
Equity / Common Stock, $0.0001 par value
Shares outstanding
81.1M
All holders as of September 30, 2025
Q3 2025
Total 13F shares, excl. options
64.3M
Holdings value
$1.08B
% of all portfolios
0.001%
Grand Portfolio weight change
+0%
Number of holders
134
Number of buys
62
Number of sells
-56
Average Value change %
+0%
Average buys %
+0%
Average sells %
0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Spyre Therapeutics, Inc. - Common Stock, $0.0001 par value (SYRE)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Fairmount Funds Management LLC 9.99% $136M 8.11M Peter Evan Harwin Oct 15, 2025
BlackRock, Inc. 6.6% $58.4M 3.96M BlackRock, Inc. Jun 30, 2025
RTW INVESTMENTS, LP 6.2% $44.3M 3.62M RTW Investments, LP Dec 31, 2024
TANG CAPITAL MANAGEMENT LLC 5.3% $39.1M 3.2M TANG CAPITAL MANAGEMENT, LLC Apr 24, 2025
VANGUARD GROUP INC 5.08% $45.2M 3.07M The Vanguard Group Jun 30, 2025
Venrock Healthcare Capital Partners III, L.P. 4.6% $32.8M 2.69M Venrock Healthcare Capital Partners III, L.P. Dec 31, 2024
PERCEPTIVE ADVISORS LLC 4.4% -56% $31.5M -$186M 2.57M -79.6% Perceptive Advisors LLC Dec 31, 2024

Institutional Holders of Spyre Therapeutics, Inc. - Common Stock, $0.0001 par value (SYRE)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 64.3M $1.08B +$12.2M $16.76 134
2025 Q2 63.6M $953M +$19.5M $14.97 128
2025 Q1 62.1M $1B +$22.2M $16.14 128
2024 Q4 59.9M $1.39B +$172M $23.28 129
2024 Q3 51.4M $1.51B +$36.7M $29.41 118
2024 Q2 50.4M $1.18B +$422M $23.51 106
2024 Q1 31.6M $1.2B +$171M $37.93 101
2023 Q4 28M $601M +$524M $21.52 54
2023 Q3 3.26M $39.9M +$39.9M $12.25 27